Pebblebrook's Q1 Call Is the Real Test. The 2026 Guidance Math Doesn't Add Up.
Pebblebrook just scheduled its Q1 2026 earnings call for April 29. The interesting number isn't on the calendar... it's the gap between their 2026 guidance and what the portfolio actually delivered last year.
Pebblebrook's full-year 2026 guidance projects Adjusted FFO per diluted share of $1.50 to $1.62. The midpoint is $1.56. They printed $1.58 in 2025. That's a company telling you, at the midpoint, that per-share cash flow might decline year-over-year... while simultaneously guiding Same-Property Total RevPAR growth of 2.25% to 4.25%. RevPAR up, FFO flat-to-down. That's a cost story, and the Q1 call on April 29 is where we find out how bad.
Let's decompose the 2025 results. Net loss of ($62.2) million, which included $48.9 million in impairment charges from dispositions. Strip those out and the operating picture improves, but not enough to celebrate. Same-Property Hotel EBITDA was $348.2 million. The 2026 Adjusted EBITDAre guidance of $325 to $339 million is lower, even at the top end. That's a 2.6% decline at best. The company completed a $525 million redevelopment program and is stepping down to $65-$75 million in normalized capex. So they've spent the money. Now they need the return. Q1 will be the first real read on whether those redeveloped assets are producing.
The balance sheet move in February was smart. New $450 million unsecured term loan maturing 2031, extended the $650 million revolver, paid off the 2027 term loan and the Hollywood Beach mortgage. That's a company clearing near-term maturities and buying runway. The question is what they need the runway for. If urban recovery in San Francisco, Chicago, and Portland accelerates, this looks like disciplined capital management. If those markets stall (and D.C. and San Diego stay soft), it looks like a company creating breathing room because it needs it.
Thirteen analysts cover this stock. Six say sell. Five say hold. One buy, one strong buy. Average target: $11.91. The stock is at $12.04. The market is telling you that Pebblebrook is fairly valued at best and possibly overvalued by consensus. The preferred shares are a different story (trading at a 20%+ discount with 5.7x coverage on 2025 Adjusted FFO), but that's a fixed-income trade, not an equity thesis. For the common, you need to believe urban full-service demand accelerates meaningfully in 2026. The guidance itself doesn't make that case.
The April 29 call matters more than usual. Not for the EPS number (consensus is $0.19-$0.23, and they'll probably beat it the way they beat Q4 by $0.08). What matters is the Same-Property RevPAR detail by market, the margin trajectory after $525 million in redevelopment, and whether management adjusts the full-year range. A company guiding to a possible net loss of ($10.4) million at the low end while growing RevPAR 2-4% is telling you that cost pressures are real and the redevelopment ROI hasn't fully materialized. If Q1 margins compress, the full-year EBITDA number is at risk... and at $325 million on the low end, that's barely covering the capital structure.
Here's the thing about Pebblebrook's numbers... they matter to you even if you don't own PEB stock. This is a 44-property, 11,000-room portfolio concentrated in the same urban markets a lot of you operate in. If their San Francisco and Chicago properties are showing RevPAR growth but margin compression, that tells you something about what labor and operating costs are doing in those markets right now. Pay attention to the April 29 call. When Bortz breaks down market-by-market performance, that's free comp set intelligence. Use it.